Science News
Discover the news and inspiring materials from the world of biotechnology.
Mabion’s Article about RFP process named one of the Top 10 Industry Insights of 2025 by Outsourced Pharma
As biologics continue to demonstrate their versatility across the pharma landscape, biotechs are looking for capable CDMOs that can bring these therapies to market to provide innovative treatment to patients with chronic diseases. Amid the vast discussion around how best to assess a CDMO’s offerings and determine whether they are equipped to fulfill a drug program’s needs, the importance of optimizing the request for proposal (RFP) is often omitted. Generally, an RFP describes the immediate needs of the proposed project, the services needed from the CDMO, projected timeline, and budget, all of which is used by a CDMO to generate a cost proposal for services to be rendered. Depending on the needs and knowledge of the sponsor, it might also detail specific technologies and key data points to be procured.
Learn more
Declaration of the objectives and scope of the European Biotech Act
The European Commission has announced the European Biotech Act, a major policy initiative aimed at strengthening the EU’s competitiveness in health biotechnology and biopharmaceutical innovation. The move responds to a growing gap between Europe’s strong scientific base and its weaker industrial and financial performance in biotech. Health biotechnology employs more than 900,000 people in the EU, around 75% of them in the health sector, and contributes close to €40 billion annually to the European economy. Despite this, the EU attracts only about 7% of global venture capital investment in health biotech, while its share of global commercial clinical trials has declined from 22% to 12% over the past decade. The Biotech Act is designed to address these challenges by reducing regulatory complexity, accelerating development timelines, and improving access to investment capital for biotech companies operating in Europe.
Learn more
AI Comes of Age in Biologic Drug Discovery
AI drug discovery is rapidly reshaping how large-molecule therapeutics are conceived, moving the industry from empirical screening toward intentional, computational design. Recent advances show that artificial intelligence can now propose entirely new antibody structures with levels of precision and functionality approaching those required for real medicines. These technologies increasingly account not only for target binding but also for properties critical to development, such as stability, specificity, and manufacturability. As a result, biological targets once considered difficult or impractical for large-molecule drugs are coming back into strategic focus. While clinical adoption will still require rigorous validation and safety testing, the trajectory suggests a fundamental shift in how biopharmaceutical innovation will unfold.
Learn more
Mabion’s Tech Transfer Team wins Biologics CDMO Excellence Europe 2025
We are incredibly proud to share that Mabion has been named Tech Transfer Team of the Year at the Biologics CDMO Excellence Europe 2025 Awards! This recognition is especially meaningful because it comes directly from our industry peers.
Learn more
Mabion named finalist in four categories at the Life Science Sales & Marketing Awards 2025
Mabion’s marketing and scientific excellence earned four finalist spots at the Life Science Sales and Marketing Awards 2025. We’re proud to announce Mabion’s selection as a finalist. The “Unlocking the Future of Therapeutics” contest leads the way in Campaign of the Year. Individual honours go to Paulina Toboła for Support Professional of the Year. In addition, Jakub Knurek is also shortlisted for Marketing Professional of the Year and the One to Watch Award.
Learn more
Mabion Awards €500,000 CDMO Services to WPD Pharmaceuticals for Breakthrough ADC Project
Mabion announced today that WPD Pharmaceuticals has been selected by the expert jury as the winner of its “Unlocking the Future of Therapeutics” innovation contest. WPD Pharmaceuticals will receive up to €500,000 in service credits for Mabion’s biologics development and manufacturing services with which it can accelerate the development of the next-generation antibody-drug conjugate (ADC) program in oncology.
Learn more
They understood how the immune system is kept in check: The 2025 Nobel prize in physiology or medicine
This year’s Nobel prize in physiology or medicine was awarded to researchers who discovered regulatory T cells (Tregs), whose role is to suppress the excessive immune response. Their discovery paves the way for innovative therapies, including antibody-drug conjugates that modulate the activity of immune system to fight cancer.
Learn more
Mabion is a Biologics CDMO Leadership Award Europe Finalist
Mabion has been honored as a 2025 CDMO Leadership Awards Europe winner in the Biologics category, marking a significant recognition of our scientific and operational excellence. This year’s edition of the awards represents the first European celebration of CDMO achievement, hosted at CPHI Frankfurt.
Learn more
Jakub Knurek became a finalist of the CPHI Pharma Awards in the Future Leader category
Jakub Knurek, a Marketing Specialist at Mabion S.A., has been named a finalist in the Future Leader category of the CPHI Pharma Awards 2025, to be awarded at CPHI Frankfurt on 28 October. The award recognizes rising talents in pharma, biopharma, academia, or research settings, with at least five years of relevant experience and a maximum age of 35 by the ceremony date.
Learn more